N11005

N11005 is an investigational oral insulin formulation developed by Beijing Hospital for the treatment of diabetes mellitus. It is designed as a prandial (mealtime) insulin intended to mimic the physiological portal delivery of insulin from the pancreas to the liver, potentially offering a more convenient and physiological alternative to traditional subcutaneous injections. By utilizing an oral delivery system, N11005 aims to improve patient compliance and glycemic control. Clinical development has included Phase 1 studies in healthy subjects to evaluate its pharmacokinetics, pharmacodynamics, and safety profile, often comparing its performance against standard subcutaneous regular human insulin (e.g., Novolin R).

Other names

oral insulin N11005